title: Emerging issues in pediatric asthma: gaps in EPR-3 guidelines for infants and children.
abstract: There are many complexities to the treatment of infants and children with recurrent wheezing and asthma. The National Heart, Lung and Blood Institute's (NHLBI's) Expert Panel Report-3 (EPR-3), published in 2007, provides guidance to clinicians who care for infants and children with asthma. Since that time, many important clinical trials have further informed the evidence base available to clinicians. In this manuscript, new approaches to long-term therapy, intermittent fixed-dose and dynamic dose therapies, and emerging therapies for asthma are reviewed. Further, additional gaps in guideline-based care and areas for future research are discussed.
authors.affiliation: Division of Allergy, Immunology and Rheumatology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue K4/936 CSC, Madison, WI, 53792-9988, USA, djj@medicine.wisc.edu.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Jackson
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology*; D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D054555:National Heart, Lung, and Blood Institute (U.S.); D017410:Practice Guidelines as Topic; D014481:United States
chemical_list: D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018680:Cholinergic Antagonists